GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Castle Biosciences
Castle Biosciences provides diagnostic tests that help determine prognosis for certain types of cancer. Its stock price reflects the growing adoption of its tests by physicians and reimbursement from insurance companies, which is key to commercial success in this field.
Share prices of companies in the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests to predict the progression of skin cancer and other diseases. We've categorized it as a "Cancer Analysis" company. The chart below shows how the market values companies improving cancer diagnostics and treatment.
Broad Market Index - GURU.Markets
Castle Biosciences is a diagnostic company that provides genetic tests to predict the progression of skin cancer and other diseases. Its innovativeness earned it a spot in the GURU.Markets index. The chart below compares its performance to the overall market.
Change in the price of a company, segment, and market as a whole per day
CSTL - Daily change in the company's share price Castle Biosciences
For Castle Biosciences, a specialist in skin cancer diagnostics, change_co is a measure of volatility in the medtech sector. Daily fluctuations reflect the reaction to the acceptance of its tests and changes in pricing. This metric is important for analyzing innovative diagnostic companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Castle Biosciences, Inc. is a cancer diagnostics company. This chart highlights the highly volatile nature of the healthcare sector. Comparing it to CSTL, which focuses on skin cancer diagnostics, helps assess how sensitive its business is to the introduction of new tests.
Daily change in the price of a broad market stock, index - GURU.Markets
Castle is a company specializing in genomic diagnostics for cancer detection. The oncology diagnostics sector is extremely sensitive to clinical data. The chart below shows the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Castle Biosciences
Castle is a leader in genomic skin cancer diagnostics. Its year-over-year performance reflects rapid growth in testing volumes and investor confidence in the potential of its technologies to improve patient care. The chart below shows the history of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Castle Biosciences, Inc. provides genetically based diagnostic tests for cancer prognosis. Its innovative products help doctors make decisions. The chart shows how its leadership in this niche and efforts to expand its testing portfolio contribute to its rapid growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Castle Biosciences, a cancer diagnostics company, operates in the defensive healthcare sector. Demand for cancer tests is unaffected by economic cycles. The company's stock price reflects the long-term trend toward personalized medicine, providing it with sustainable growth potential.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Castle Biosciences
Galiano, a gold mining company with assets in Ghana, has monthly fluctuations that reflect gold prices, as well as the operational and political risks associated with operating in West Africa. This makes it more volatile than its North American competitors.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
Castle Biosciences provides diagnostic tests that help doctors make treatment decisions for skin cancer and other diseases. The molecular diagnostics sector is one of the fastest-growing in medicine. The industry's momentum reflects investors' faith in personalized medicine, and Castle strives to become a leader in its niche with its unique tests.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Castle Biosciences, Inc. is a diagnostic company that provides genetic tests that help determine prognosis and select treatments for various types of cancer, primarily skin cancer. Its business depends on physician acceptance of its tests. The broader market graph allows us to assess the extent to which its innovative products, which provide unique information, have gained market share, regardless of general sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Castle Biosciences
Castle Biosciences provides diagnostic tests for prognosis in various types of cancer. Weekly stock performance depends on testing volumes, reimbursement rates, and the release of data supporting the value of its tests.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
Castle Biosciences is a cancer diagnostics company. Comparing its weekly performance with the healthcare sector reveals its uniqueness. The chart clearly demonstrates how regulatory decisions on Medicare rates are causing its shares to take on a life of their own, separate from general industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Castle, a diagnostics company, shares live in a world of their own. Their performance is determined by the decisions of insurance companies. A chart comparing them to the S&P 500 clearly demonstrates how the stock can move independently of the broader market.
Market capitalization of the company, segment and market as a whole
CSTL - Market capitalization of the company Castle Biosciences
Castle Biosciences's valuation is a story of how genetic testing can improve diagnostics and prognosis in dermatology and oncology. The company's stock price, which offers tests for melanoma and other cancers, reflects investors' faith in personalized medicine.
CSTL - Share of the company's market capitalization Castle Biosciences within the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer and other diseases. Its sector share reflects its leadership in dermatologic oncology. The chart below shows this innovator's position in personalized medicine.
Market capitalization of the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests for prognosis in various cancers, particularly melanoma. The chart below shows the overall market capitalization of the cancer analysis sector, reflecting the growing role of genomics in clinical decision-making.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows diagnostics that save lives. Castle Biosciences develops genetic tests that help determine prognosis and select treatments for skin cancer and other tumors. Its market cap reflects how personalized medicine is changing oncology.
Book value capitalization of the company, segment and market as a whole
CSTL - Book value capitalization of the company Castle Biosciences
Castle Biosciences' capital comes from its laboratories and a portfolio of patents for diagnostic tests that help predict the progression of skin cancer and other diseases. This represents both scientific and commercial capital. The chart shows how the company, while holding a dominant position in its niche, grows its capital base through the commercialization of its tests.
CSTL - Share of the company's book capitalization Castle Biosciences within the market segment - Cancer analysis
Castle Biosciences provides diagnostic tests that help predict cancer progression. Its strength lies in its certified laboratories and unique algorithms. The chart shows the company's share of physical laboratory infrastructure for oncology diagnostics.
Market segment balance sheet capitalization - Cancer analysis
Cancer diagnostics like Castle Biosciences' require high-tech laboratories. Compared to its healthcare assets, this makes the company moderately capital-intensive. Its tests rely on complex and expensive physical infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Castle Biosciences' assets are not drugs, but cutting-edge laboratories that conduct genomic tests that help doctors determine prognosis and treatment strategies for various types of cancer, particularly melanoma. The book value reflects the technology platform for this predictive diagnostic. The chart shows its scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Castle Biosciences
Castle Biosciences, a cancer diagnostics company, is valued by the market at multiples of its lab value. Investors are paying for its portfolio of unique genomic tests, which provide doctors with valuable prognostic information and help them choose treatment strategies.
Market to book capitalization ratio in a market segment - Cancer analysis
Castle Biosciences provides diagnostic tests that help doctors make treatment decisions for skin cancer and other diseases. Its value lies in its unique data and algorithms. The chart shows the high premium the market pays for its innovations in personalized medicine.
Market to book capitalization ratio for the market as a whole
Castle Biosciences is a diagnostic company that provides genetic tests that help determine prognosis and select treatments for various types of cancer, particularly melanoma. Its value lies in its unique tests and data. This metric reflects the premium the market places on personalized medicine, which helps doctors make more accurate decisions.
Debts of the company, segment and market as a whole
CSTL - Company debts Castle Biosciences
Castle Biosciences, a company providing diagnostic tests for cancer prognosis, funds its growth and development of new tests through strong cash flow from existing products. The company maintains a debt-free balance sheet. This chart demonstrates financial self-sufficiency based on a unique and profitable niche.
Market segment debts - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make decisions about cancer treatment, primarily skin cancer. This chart shows how the company, operating in the niche but important field of oncology, uses capital to conduct research to validate the value of its tests and to commercialize them.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer and other diseases. Developing and commercializing these tests requires investment in R&D and laboratory capacity. This chart shows how the company uses debt to finance its growth in the innovative field of oncology diagnostics.
Market segment debt to market segment book capitalization - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests for prognosis in various types of cancer, particularly melanoma. This chart shows how the company finances its research and laboratory operations. It compares its debt to the market capitalization of the entire medical diagnostics sector, reflecting its financial strategy.
Debt to book value of all companies in the market
Castle Biosciences provides diagnostic tests that help determine prognosis for various types of cancer. Medical diagnostics is a knowledge-intensive industry. Does the company finance its research and development with debt? This chart of total market debt provides context for assessing its financial strategy and independence from creditors.
P/E of the company, segment and market as a whole
P/E - Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests to predict the progression of skin cancer and other diseases. This chart shows how investors value its niche but high-margin products. This valuation depends on physician acceptance of its tests and the expansion of insurance coverage.
P/E of the market segment - Cancer analysis
Castle Biosciences is a diagnostics company that provides personalized genetic information to improve cancer treatment decisions, primarily for melanoma and other skin cancers. This chart shows the average rating for the sector, which helps understand how the market values its prognostic tests.
P/E of the market as a whole
Castle Biosciences is a diagnostic company that provides genetic tests to predict the progression of cancer, primarily skin cancers. This helps doctors choose treatments. Does its high rating reflect a general interest in personalized medicine, or is it a unique belief in the accuracy of its tests and the ability to gain broad insurance coverage?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors determine prognosis and select treatments for various types of cancer, particularly melanoma. This graph reflects future revenue expectations, which depend on the adoption of its tests into clinical standards and insurance reimbursement levels.
%20P%2FE%20Castle%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Castle-Biosciences&v=1772574419886 "Chart of the company's future (projected) P/E Castle Biosciences")
Future (projected) P/E of the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors determine prognosis and choose treatments for patients with skin cancer and other diseases. The chart shows forecasts for the medical diagnostics sector. This helps assess the market's confidence in the clinical value of Castle's tests and their potential to become a standard of care.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772574419893 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Castle Biosciences, Inc. provides diagnostic tests that help doctors make treatment decisions for skin cancer and other diseases. The company operates at the intersection of genetics and oncology. This market sentiment graph influences how investors evaluate innovative companies in the field of personalized medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772574419912 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer and other diseases. Revenue is based on the number of tests sold. This chart illustrates how innovations in diagnostics and personalized medicine can be successfully commercialized.
Profit of companies in the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests that help determine prognosis and tailor treatments for skin cancer and other diseases. This chart, showing profitability in the cancer testing sector, demonstrates how personalized medicine is becoming a reality. Their tests provide doctors and patients with valuable information for making life-changing decisions.
Overall market profit
Castle Biosciences is a diagnostic company that provides genetic tests for predicting cancer progression, primarily melanoma. This helps doctors choose the right treatment strategy. The company's growth depends on the implementation of personalized medicine. Overall economic stability, reflected in this chart, is important for healthcare funding and the adoption of new technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer (melanoma) and other types of cancer. This chart reflects analysts' forecasts for the growth of testing and the expansion of its diagnostic product portfolio, which is important for personalized medicine.
%20profit%20of%20the%20company%20Castle%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Castle-Biosciences&v=1772574420355 "Graph of future (projected) profit of the company Castle Biosciences")
Future (predicted) profit of companies in the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer and other diseases. Its growth depends on the adoption of its tests in clinical practice. This chart for the medical diagnostics sector reflects expectations for the growth of personalized medicine and demand for innovative tests.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772574420387 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
Castle Biosciences provides diagnostic tests to aid in the treatment of skin cancer. Demand for its services depends on advances in medicine and insurance coverage. General economic expectations, reflected in this graph, may indirectly influence healthcare funding and the adoption of new diagnostic technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772574420408 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make decisions about treating skin cancer and other diseases. The chart shows a high valuation per dollar of its revenue. This reflects the value of its tests for personalized medicine and investors' confidence in the growth of the oncology diagnostics market.
P/S market segment - Cancer analysis
Castle Biosciences provides diagnostic tests that help determine prognosis for various types of cancer, primarily skin cancer. The company's revenue is growing as its tests are adopted into clinical practice. This chart reflects the average valuation in the sector, providing insight into how investors view the value of the information Castle's tests provide.
P/S of the market as a whole
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer and other diseases. This chart, showing the average market revenue estimate, helps understand the premium investors are willing to pay for innovative diagnostic tools that improve patient outcomes and personalize medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer and other diseases. Its growth is driven by innovation. This chart reflects investor expectations for the future clinical adoption of its tests and the development of new diagnostic products.
%20P%2FS%20Castle%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Castle-Biosciences&v=1772574420502 "The graph of the company's future (projected) P/S Castle Biosciences")
Future (projected) P/S of the market segment - Cancer analysis
Castle Biosciences is a diagnostics company that provides prognostic information to doctors and patients through genetic tests for various types of cancer, primarily skin cancer. This chart shows the average estimated future sales in the medical diagnostics sector. It helps understand how the market perceives the potential of Castle Biosciences' tests to improve treatment.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772574420530 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors determine prognosis and choose treatment strategies for patients with skin cancer and other types of oncology. This indicator reflects collective market expectations. Castle's growth reflects the trend toward personalized medicine, where decisions are made based on the unique tumor profile.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772574420564 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Castle Biosciences
This chart illustrates the sales of Castle Biosciences, a company that provides diagnostic tests that help determine prognosis and select treatments for various types of cancer, particularly melanoma. Revenue is generated from these tests. The trend reflects the growing demand for personalized medicine in oncology.
Sales of companies in the market segment - Cancer analysis
Castle Biosciences provides diagnostic tests that help doctors and patients make more informed decisions when treating skin cancer and other diseases. This chart shows the growth of the oncology diagnostics market. Castle's products assess tumor aggressiveness and the risk of metastasis, a key element of personalized medicine.
Overall market sales
Castle Biosciences is a diagnostic company that provides tests to predict the progression of skin cancer and other diseases. Demand for its services is growing with the advancement of personalized medicine. The overall economic situation, reflected in this chart, is influencing healthcare funding and the implementation of innovative tests.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help determine prognosis and select treatments for various types of cancer, particularly melanoma. The chart reflects analysts' expectations for growth in the personalized cancer diagnostics market.
%20sales%20of%20the%20company%20Castle%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Castle-Biosciences&v=1772574420741 "Schedule of future (projected) sales of the company Castle Biosciences")
Future (projected) sales of companies in the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer, particularly melanoma. The company's tests assess tumor aggressiveness. This chart shows the forecast for the cancer testing market, where Castle Biosciences occupies an important niche in dermatological oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772574420791 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Castle Biosciences is a diagnostic company that provides genetic tests for cancer prognosis, primarily for melanoma and other skin cancers. Demand for its tests helps doctors make treatment decisions. This chart illustrates general trends in healthcare, and Castle's growing testing volume reflects the advancement of personalized medicine in oncology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772574420819 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make decisions about cancer treatment, primarily melanoma. The company's profitability depends on the number of tests performed and their payment. This chart shows how the company monetizes its unique prognostic information, helping personalize cancer treatment.
Market segment marginality - Cancer analysis
Castle Biosciences provides diagnostic tests that help doctors and patients make more informed decisions about cancer treatment, particularly for melanoma and other skin cancers. Profitability depends on the adoption of their tests in clinical practice. This chart shows operational results. Their outperformance over competitors speaks to the value of their prognostic information.
Market marginality as a whole
Castle Biosciences is a diagnostic company that provides genetic tests to help doctors make treatment decisions for skin cancer (melanoma) and other types of cancer. This overall profitability curve is irrelevant to them. Their business is driven by innovation, the clinical utility of their tests, and their integration into standard medical care.
Employees in the company, segment and market as a whole
Number of employees in the company Castle Biosciences
Castle Biosciences is a diagnostic company that provides genetic tests for cancer prognosis. Its team includes lab technicians, scientists, and a sales team. The growth in this graph reflects the increase in testing volumes and the successful implementation of its tests into clinical practice.
Share of the company's employees Castle Biosciences within the market segment - Cancer analysis
Castle Biosciences provides diagnostic tests that help doctors make more informed decisions when treating skin cancer and other diseases. This graph shows the company's scientific expertise in its niche. Behind it lies a team of scientists and lab technicians who perform complex analyses that provide personalized information about disease prognosis.
Number of employees in the market segment - Cancer analysis
Castle Biosciences, Inc. is a company that provides diagnostic and prognostic tests based on genetic information for various types of cancer, particularly skin cancer. This chart shows employment trends in the oncology diagnostics sector. The growth in the number of geneticists and sales specialists reflects the growing role of personalized medicine in oncology and the demand for tests that support physician decision-making.
Number of employees in the market as a whole
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make treatment decisions for skin cancer and other types of cancer. Its tests provide prognostic information. This figure demonstrates how personalized medicine and the advanced diagnostics offered by Castle are changing the approach to cancer treatment and creating jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Castle Biosciences (CSTL)
Castle Biosciences is a diagnostic company that provides skin cancer prognostic tests. This chart reflects the high value of its intellectual capital. The company's key assets are its proprietary prognostic tests and data. The chart shows how highly the market values these unique, science-intensive products and their market potential per employee.
%20of%20the%20company%20Castle%20Biosciences%20(CSTL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Castle-Biosciences-CSTL&v=1772574421357 "Chart of market capitalization per employee (in thousands of dollars) of the company Castle Biosciences (CSTL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides tests that help predict the progression of cancer, primarily melanoma. Its value lies in its unique algorithms and clinical data. This chart demonstrates the market's high appreciation for its intellectual property and ability to provide valuable information to doctors and patients.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772574421430 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Castle Biosciences is a diagnostic company that provides genetic tests that help doctors make decisions about cancer treatment. This chart shows how the market values this leader in a niche medical field. Its high cost per employee reflects the value of its unique tests and the underlying scientific data.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772574421503 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Castle Biosciences (CSTL)
Castle Biosciences provides diagnostic tests that help doctors determine prognosis and treatment for patients with skin cancer and other diseases. It's a high-margin diagnostic business. This chart shows how the company monetizes its unique tests. This efficiency is driven by high margins on diagnostic services.
%20Chart%20Castle%20Biosciences%20(CSTL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Castle-Biosciences-CSTL&v=1772574421554 "Company Profit Per Employee (in thousands of dollars) Chart Castle Biosciences (CSTL)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Castle Biosciences (CSTL) is a company that provides diagnostic tests (based on gene expression) for cancer prognosis, primarily in dermatology (melanoma). It is a high-margin laboratory business. This metric reflects how successfully their sales team promotes these tests.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772574421630 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Castle Biosciences (CSTL) is a biotech company providing genetic tests (DecisionDx) for cancer diagnosis and prognosis (primarily skin cancer). Like Myriad, it offers both R&D and services. This chart shows how their unique tests (margin) are in demand by dermatologists and covered by insurance companies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772574421648 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Castle Biosciences (CSTL)
Castle Biosciences is a diagnostic company that provides genetic tests to predict the progression of skin cancer and other diseases. This chart shows the commercial success of its unique tests. The growth in revenue per employee demonstrates the widespread use of its tests by dermatologists and oncologists, which helps inform treatment decisions.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Castle-Biosciences-CSTL&v=1772574421704 "Sales chart per company employee Castle Biosciences (CSTL)")
Sales per employee in the market segment - Cancer analysis
Castle Biosciences (CSTL) provides diagnostic tests (based on gene analysis) that help doctors make decisions about cancer treatment, particularly for melanoma. This graph shows the revenue generated by each of their employees (geneticists, lab technicians). This allows us to assess their productivity in the oncology diagnostics segment.
Sales per employee for the market as a whole
Castle Biosciences (CSTL) is a company that provides diagnostic tests (based on gene analysis) for prognosis in various types of cancer (such as melanoma). It's a knowledge-intensive business. This chart shows how effectively the company is monetizing its unique laboratory tests. The growth in this indicator indicates the successful implementation of their diagnostics into medical practice.
Short shares by company, segment and market as a whole
Shares shorted by company Castle Biosciences (CSTL)
Castle Biosciences is a company that provides genetic-based diagnostic tests for prognosis in various cancers (such as melanoma). The bearish sentiment shown in this chart may be due to concerns about the clinical utility of its tests or regulatory pressure on insurance reimbursement.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Castle-Biosciences-CSTL&v=1772574421857 "Short Shares Chart for the Company Castle Biosciences (CSTL)")
Shares shorted by market segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides genetic tests for cancer prognosis, primarily melanoma and other skin cancers. This metric measures pessimism. "Short" here is a bet that their tests are ineffective or that insurance companies (Medicare) will refuse to cover them.
Shares shorted by the overall market
Castle Biosciences (CSTL) is a diagnostic company that provides doctors with information to treat skin cancer and other diseases. It's a growth sector driven by innovation. This chart shows the overall "risk appetite" in the market. When it rises, investors panic and often sell off growth stocks, especially in biotech that haven't yet achieved stable profitability, in favor of "safe" assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Castle Biosciences (CSTL)
Castle Biosciences is a diagnostics company whose success depends on the adoption of its cancer tests and, more importantly, Medicare rates. This chart measures how investors react to this news. It shows when optimism about rates (overbought) or fears of competition (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Castle-Biosciences-CSTL&v=1772574421886 "RSI 14 indicator chart for the company's stock Castle Biosciences (CSTL)")
RSI 14 Market Segment - Cancer analysis
Castle Biosciences is a diagnostic company that provides gene expression-based tests (for example, for melanoma). Their tests help doctors assess the aggressiveness of cancer and choose treatment. This graph measures the collective excitement in the oncology diagnostics sector. It helps understand whether the entire segment is overheated by expectations for new technologies.
RSI 14 for the overall market
Castle Biosciences (CSTL), a cancer diagnostics company, is critically dependent on sentiment, as reflected in this chart. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. During moments of market panic, investors flee unprofitable biotechs, making it more difficult for cash-burning companies.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CSTL (Castle Biosciences)
Castle Biosciences is a company that provides diagnostic tests (DecisionDx) for predicting the progression of rare cancers, primarily melanoma. This chart shows the analysts' average 12-month forecast. It reflects their assessment of how actively oncologists will implement these tests in clinical practice.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CSTL-Castle-Biosciences&v=1772574422058 "A chart showing analyst consensus forecasts for the expected stock price. CSTL (Castle Biosciences)")
The difference between the consensus estimate and the actual stock price CSTL (Castle Biosciences)
Castle Biosciences (CSTL) is a diagnostic company focused on skin cancer. Its genetic tests help doctors assess the aggressiveness of melanoma and choose treatment. This is a high-margin niche. This chart shows the difference between the consensus estimate and the price. It reflects whether analysts believe in the growth of these niche tests.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CSTL-Castle-Biosciences&v=1772574422116 "A chart showing the difference between the consensus forecast and the actual stock price. CSTL (Castle Biosciences)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Castle Biosciences (CSTL) is a company that provides smart diagnostic tests that use AI and genomics to predict the aggressiveness of skin cancer (melanoma). This chart shows general expectations for the oncology testing sector. It reflects whether experts believe demand for predictive tests in oncology will grow.
Analysts' consensus forecast for the overall market share price
Castle Biosciences (CSTL) is a high-tech diagnostic company for skin cancer (melanoma) and other rare types. This chart, reflecting the economic consensus, is a barometer for them. During a recession (pessimism), patients skimp on dermatologist visits, and insurers are reluctant to approve expensive tests.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Castle Biosciences
Castle Biosciences is a skin cancer diagnostician. They provide genomic tests that help doctors determine the aggressiveness of melanoma and other tumors and choose treatment strategies. This chart is an indicator of the acceptance of their tests. It likely aggregates the volume of tests performed and their ability to prove the value of their prognostic information to doctors and insurers.
AKIMA Market Segment Index - Cancer analysis
Castle (CSTL) is an innovator in dermatology diagnostics; the company provides unique genomic tests that help doctors determine the aggressiveness of skin cancer (melanoma). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does this niche (skin cancer) diagnostic model (CSTL) differentiate itself from the average pharmaceutical company?
The AKIM Index for the overall market
Castle Biosciences is a diagnostic company providing genomic tests for dermatology (skin cancer), gastroenterology, and mental health. This chart, reflecting the market average, is a backdrop. It helps assess how the CSTL market, which helps doctors make treatment decisions, compares to overall macroeconomic trends in medicine.
